Last $60.89 USD
Change Today -0.48 / -0.78%
Volume 1.8M
BMRN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Daniel K. Spiegelman B.A., M.B.A.

Chief Financial Officer and Executive Vice President, BioMarin Pharmaceutical Inc.
AgeTotal Calculated CompensationThis person is connected to 68 board members in 4 different organizations across 9 different industries.

See Board Relationships
54$8,918,292
As of Fiscal Year 2012

Background*

Mr. Daniel K. Spiegelman, also known as Dan, B.A., M.B.A. has been the Chief Financial Officer and Executive Vice President of BioMarin Pharmaceutical Inc. since May 2012. Mr. Spiegelman co-founded Rapidscan Pharma Solutions, Inc., in 2010 and serves as its Chief Executive Officer. He served as the Chief Financial Officer and Senior Vice President of Gilead Palo Alto, Inc. since September 1999 and served as its Principal Accounting Officer. Mr. Spiegelman served as the ...

Read Full Background

Corporate Headquarters*

770 Lindaro Street
San Rafael, California 94901

United States

Phone: 415-506-6700
Fax: 415-382-7889

Board Members Memberships*

Director
2004-2012
Former Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee
2004-N/A
Former Independent Director, Chairman of Audit Committee and Member of Dividend Committee
2006-Present
Director
2008-Present
Director, Chairman of Audit Committee and Member of Corporate Governance & Nominating Committee
2009-2012
Former Director and Chairman of Audit Committee
2010-Present
Director and Chairman of Audit Committee

Education*

MBA
Stanford Graduate School of Business
BA
The Board of Trustees of The Leland Stanford Junior University

Other Affiliations*

Annual Compensation*

Salary$250,462
Bonus$350,000
Total Annual Compensation$600,462

Stock Options*

Restricted Stock Awards$5,889,980
All Other Compensation$4,000
Exercisable Options18,229
Exercisable Options Value$184,842
Unexercisable Options106,771
Unexercisable Options Value$1,082,658
Total Value of Options$1,267,500
Total Number of Options125,000

Total Compensation*

Total Annual Cash Compensation$842,062
Total Short Term Compensation$600,462
Other Long Term Compensation$5,893,980
Total Calculated Compensation$8,918,292
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $60.89 USD -0.48

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$810.2K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.0M
John H. Johnson Executive Chairman, Chief Executive Officer and President
Dendreon Corp.
$736.4K
Rajesh C. Shrotriya M.D.Chairman, Chief Executive Officer, President, Chairman of Placement Committee and Chairman of Product Acquisition Committee
Spectrum Pharmaceuticals, Inc.
$2.4M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$722.2K
Compensation as of Fiscal Year 2013.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.